Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.25, $0.03 better than the analyst estimate of $0.22. Revenue for the quarter came in at $146.81 million versus the consensus estimate of $141.19 million.

GUIDANCE:

Corcept Therapeutics sees FY2024 revenue of $620-650 million, versus the consensus of $610.6 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.